$22.30
1.76% today
Nasdaq, Feb 28, 04:43 pm CET
ISIN
US98419J2069
Symbol
XOMA
Sector
Industry

XOMA Corporation Stock price

$22.70
-4.56 16.73% 1M
-6.77 22.97% 6M
-3.58 13.62% YTD
-1.66 6.81% 1Y
+0.77 3.51% 3Y
-1.08 4.54% 5Y
-51.10 69.24% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.23 1.00%
ISIN
US98419J2069
Symbol
XOMA
Sector
Industry

Key metrics

Market capitalization $267.47m
Enterprise Value $243.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.27
P/S ratio (TTM) P/S ratio 12.38
P/B ratio (TTM) P/B ratio 3.15
Revenue growth (TTM) Revenue growth 389.82%
Revenue (TTM) Revenue $21.61m
EBIT (operating result TTM) EBIT $-15.40m
Free Cash Flow (TTM) Free Cash Flow $-15.55m
Cash position $142.92m
EPS (TTM) EPS $-3.48
P/E forward negative
P/S forward 9.38
EV/Sales forward 8.54
Short interest 1.97%
Show more

Is XOMA Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

XOMA Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a XOMA Corporation forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a XOMA Corporation forecast:

Buy
67%
Hold
33%

Financial data from XOMA Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
22 22
390% 390%
100%
- Direct Costs 0.23 0.23
75% 75%
1%
21 21
511% 511%
99%
- Selling and Administrative Expenses 35 35
39% 39%
160%
- Research and Development Expense 2.04 2.04
1,260% 1,260%
9%
-15 -15
29% 29%
-70%
- Depreciation and Amortization 0.23 0.23
75% 75%
1%
EBIT (Operating Income) EBIT -15 -15
31% 31%
-71%
Net Profit -30 -30
12% 12%
-139%

In millions USD.

Don't miss a Thing! We will send you all news about XOMA Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

XOMA Corporation Stock News

Neutral
GlobeNewsWire
3 days ago
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has cl...
Neutral
GlobeNewsWire
4 days ago
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March.  Management will also participate in one-on-one investor meetings.
Neutral
GlobeNewsWire
24 days ago
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025.
More XOMA Corporation News

Company Profile

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Head office United States
CEO Owen Hughes
Employees 13
Founded 1981
Website www.xoma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today